Attention Deficit Hyperactivity Disorder (ADHD) News and Research

RSS

Attention Deficit Hyperactivity Disorder (ADHD)

Attention deficit-hyperactivity disorder (ADHD) is a neurobehavioral disorder that affects 3-5 percent of all American children. It interferes with a person's ability to stay on a task and to exercise age-appropriate inhibition (cognitive alone or both cognitive and behavioral).

ADHD linked to poorer eating habits: Study

A new study by researchers in Perth has linked attention-deficit hyperactivity disorder with “western-style” diets in teenage sufferers. For the study the Telethon Institute for Child Health and Research examined the diets of 1,800 adolescents, categorizing them as either eating a healthy mix of fruit, vegetables, whole grains and fish or the “western-style” highly-processed, fried and take-away foods. The latter contained more food additives, flavors or colors, which could lead to hyperactivity or changes to chemicals that control parts of the brain dealing with attention and concentration say researchers.

29 Jul 2010

FDA approves Tris Pharma's first-time generic of Methylphenidate Hydrochloride Oral Solution

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced that the US Food and Drug Administration (FDA) has approved a first-time generic of Methylphenidate Hydrochloride Oral Solution equivalent to brand name Methylin® Oral Solution marketed by Shionogi Pharmaceuticals, Inc.

28 Jul 2010

Students with ADHD less likely to finish high school graduation: Study

Teens with attention-deficit/hyperactivity disorder - the most common childhood psychiatric condition in the United States - are less likely to finish high school on time than students with other mental-health disorders that often are considered more serious, a large national study by researchers at the UC Davis School of Medicine has found. The study found that nearly one third of students with ADHD, twice the proportion as students with no psychiatric disorder, either drop out or delay high school graduation.

28 Jul 2010

Journal of Mental Health features special issue on diagnosing mental illness

This month Journal of Mental Health features a special issue on diagnosing mental illness. The issue - which comes out just weeks after the eagerly-awaited new draft of the Diagnostic and Statistical Manual of Mental Disorders, the global diagnostic 'bible' for the field of mental health medicine - includes a series of articles written by high profile mainstream personalities on what a diagnosis of mental illness has meant to them.

27 Jul 2010

Need for better understanding of appropriate treatment choices for children with insomnia: Study

A new survey of child psychiatrists indicates that insomnia is a major problem among children in mental health treatment and at least a quarter of these patients are given sleep medication. The results of the survey, conducted by Judith Owens, MD, a sleep expert with Hasbro Children's Hospital, and colleagues, suggests that management of insomnia in this population is a common practice, although the clinical approach varies widely. The study is published in the August 2010 edition of Sleep Medicine.

27 Jul 2010

Call for greater support in mental health services for children

As support for funds for mental ailments mounts, a coalition of mental health experts are lobbying for greater support for mental health services for children. The coalition comprises The Royal Australian and New Zealand College of Psychiatrists; the Australian Psychological Society; NIFTeY (National Investment for the Early Years); the Australian Infant, Child, Adolescent and Family Mental Health Association; the Australian Association of Infant Mental Health, and the Australian Child and Adolescent Trauma, Loss and Grief Network.

22 Jul 2010

Euthymics Bioscience completes $24 million Series A financing

Euthymics Bioscience, Inc., a clinical-stage company developing next-generation antidepressants, today announced the completion of a Series A financing -- led by Novartis Venture Funds and Venture Investors - for a total investment commitment of $24 million in milestone-conditioned tranches. Hambrecht & Quist Capital Management, LLC, GBS Venture Partners and the State of Wisconsin Investment Board also participated in the financing.

22 Jul 2010

Polyfluoroalkyl chemicals linked to ADHD in children

A new study led by a team of Boston University School of Public Health researchers suggests a link between polyfluoroalkyl chemicals (PFCs), industrial compounds which are widely used in many consumer products, and attention deficit hyperactivity disorder (ADHD) in children.

21 Jul 2010

Artificial colours in food linked to cancer and behavioral disorders in children: Study

Artificial colours in foods, scientists have found may increase the risk of getting cancer, allergies and may trigger hyperactivity in susceptible children. This new report entitled, “Food Dyes: A Rainbow of Risks”, has come from the research conducted by the Centre for Science in the Public Interest (CSPI).

18 Jul 2010

Supernus initiates SPN812 Phase IIa clinical trial for ADHD in adults

Supernus Pharmaceuticals, Inc. today announced the initiation of a Phase IIa U.S. clinical trial of its product candidate SPN812 for the treatment of ADHD in adults. The trial is a proof-of-concept, randomized, double-blind, placebo-controlled study in healthy adults aged 18 to 64, inclusive, with ADHD. Supernus expects to enroll 50 subjects in the study at 5 sites across the United States.

14 Jul 2010

Officials look to stop 'medicalization' to stem health care costs

The Florida Times-Union: Stopping the "medicalization" of good health is being targeted again by economists and policymakers as a way to stem health care costs. "If Americans would stop thinking of certain problems in a medical context, experts argue, it might chip away at the more than $2 trillion the nation spends annually on health care.

9 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Free seminar to help parents understand signs and characteristics of ADHD

Learning Lab, Brentwood will present a free seminar, Does My Child Have ADHD? Diagnosing and What's Next?, on Thursday June 24, 2010 from 7:00-8:00 PM at the Maryland Farms YMCA in Brentwood. The seminar will be presented by Dr. David Elkins, Clinical Psychologist and Supervising Psychologist of Learning Lab, and Vanessa Adams, School Psychologist of Learning Lab, Brentwood.

24 Jun 2010

Study finds anxiety/panic disorder as most-disabling psychiatric disorder associated with TS

An assessment of patients with adult Tourette syndrome (TS) to identify clinical factors that contribute to psychosocial and occupational disabilities resulting from the vocal or motor tics that define TS found that anxiety/panic disorder may be the most disabling psychiatric condition associated with the disorder.

18 Jun 2010

New data shows Ohio children with special health care needs have inadequate insurance coverage

A third of Ohio children with special health care needs have unstable or inadequate insurance coverage despite the fact that they may qualify for government health programs, according to a new data analysis by the Child Policy Research Center at Cincinnati Children's Hospital Medical Center.

16 Jun 2010

Kendle offers BNA imaging technology for monitoring brain electro-physiological network activity

Kendle, a leading, global full-service clinical research organization, today announced it now offers Brain Network Activation imaging providing a non-invasive platform for mapping, monitoring and understanding brain electro-physiological network activity in response to cognitive or physiological stimuli. The BNA imaging technology was developed by ElMindA, a medical technology development company based in Herzliya, Israel.

15 Jun 2010

Healthcore Media launches dynamic, educational and community-oriented health website

Healthcore Media, LLC has launched http://www.onehealth.com, a dynamic, educational and community-oriented health website that is quickly taking center stage among health portals. Chronic illnesses are at an all-time high, and unbiased medical information and supportive connections with others are taking top priority across the world. One Health has answered the call.

14 Jun 2010

Study finds 18% of pediatric patients at-risk for sleep-related breathing disorders

According to new research that will be presented on Saturday, June 5, at the 19th Annual Meeting of the American Academy of Dental Sleep Medicine, an estimated 18 percent of pediatric patients in a University of North Carolina-based study were at-risk for sleep-related breathing disorders (SRBD). Importantly, pediatric risk was not associated with any demographic or craniofacial characteristics, as it is in adults, making it difficult to detect.

5 Jun 2010

Socioeconomic factors predict ADHD-medication in Swedish schoolchildren

A major study of more than a million children has found strong links between receiving medication for attention deficit hyperactivity disorder (ADHD) and limited maternal education, single parent families and welfare benefits, according to the June issue of Acta Paediatrica.

1 Jun 2010

Study demonstrates efficacy of CONCERTA in treating ADHD in presence of comorbid learning disability

Turning in assignments, following instructions and focusing on learning something new are among the daily classroom challenges for children with Attention Deficit Hyperactivity Disorder (ADHD), according to the National Institute of Mental Health (NIMH). New data presented today show efficacy of CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) on ADHD symptoms in children with the condition who also may face other specific challenges.

26 May 2010